Dzuveo (sufentanil)
- Region
- 🇪🇺 EU
- Active substance
- sufentanil
- Company
- Laboratoire Aguettant
- Status
- Authorised
- Therapeutic area
- Pain
- CHMP opinion
- Thu 26 Apr 2018
- EU approval
- Mon 25 Jun 2018
- Application
- EMEA/H/C/004335
- ATC
- N01AH03
- Official record
- www.ema.europa.eu
Indication
Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 KemSu Refused · Proveca Pharma Limited
- 🇪🇺 Zalviso Withdrawn · FGK Representative Service GmbH
Follow Dzuveo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.